Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and OS in CLDN18.2+HER2 mG GEJ adenocarcinoma from dr kohei shitara Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Dr Kohei Shitara speaks to ecancer as part of ASCO GI 2023 about his study looking at zolbetuximab plus mFOLFOX6 as 1L treatment for CLDN18.2+/ HER2 metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.nnHe explains that patients were randomised 1:1 to zolbetuximab plus mFOLFOX6 or placebo plus mFOLFOX6.nnDr Shitara reports that PFS was significantly improved with zolbetuximab, a statistically significant 10.6 months compared with 8.7 months.nnSign up to ecancer for free to re
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)